Zoetis Receives FDA EUA for Simparica Trio in Dogs
PARSIPPANY, N.J., August 13, 2026 Zoetis Inc. announced that the U.S. Food and Drug Administration has issued an Emergency...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARSIPPANY, N.J., August 13, 2026 Zoetis Inc. announced that the U.S. Food and Drug Administration has issued an Emergency...
Toronto, Ontario, Canada, USA 10, 2026 Creyos has announced initial results from its implementation of digital cognitive testing across...
Johns Creek, Georgia, August, USA 10, 2026 Boehringer Ingelheim Animal Health is highlighting the next generation of veterinary researchers...
Indianapolis, Indiana, USA, August 8, 2026 Elanco Animal Health has received an Emergency Use Authorization (EUA) from the U.S....
INGELHEIM, Germany, July 15, 2026 Boehringer Ingelheim reported strong financial and operational performance for the first half of 2026,...
Rockville, Maryland, June 26, 2026 OS Animal Health announced the peer-reviewed publication of Phase 2 clinical trial results evaluating...
INDIANAPOLIS, June 15, 2026 Elanco Animal Health Incorporated has announced that the U.S. Department of Agriculture (USDA) has approved...
RAHWAY, N.J., June 12, 2026 The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™...
SILVER SPRING, Maryland, June 11, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
